Hookipa Pharma Inc. (HOOK)

$0.7649

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Hookipa Pharma Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 2.67M → 7.40M (in $), with an average increase of 34.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -18.01M → -24.81M (in $), with an average decrease of 18.0% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 48.8% return, outperforming this stock by 44.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 237.7% return, outperforming this stock by 331.3%

Performance

  • $0.75
    $0.79
    $0.76
    downward going graph

    1.13%

    Downside

    Day's Volatility :5.47%

    Upside

    4.39%

    downward going graph
  • $0.41
    $2.05
    $0.76
    downward going graph

    46.05%

    Downside

    52 Weeks Volatility :80.0%

    Upside

    62.93%

    downward going graph

Returns

PeriodHookipa Pharma Inc.Sector (Health Care)Index (Russel 2000)
3 Months
15.86%
-0.7%
0.0%
6 Months
57.71%
7.7%
0.0%
1 Year
4.0%
3.3%
-1.7%
3 Years
-93.63%
13.9%
-20.7%

Highlights

Market Capitalization
75.7M
Book Value
$0.91
Earnings Per Share (EPS)
-0.86
Wall Street Target Price
4.7
Profit Margin
0.0%
Operating Margin TTM
-244.76%
Return On Assets TTM
-32.0%
Return On Equity TTM
-84.81%
Revenue TTM
20.1M
Revenue Per Share TTM
0.21
Quarterly Revenue Growth YOY
-5.4%
Gross Profit TTM
-53.0M
EBITDA
-81.4M
Diluted Eps TTM
-0.86
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.36
EPS Estimate Next Year
-0.51
EPS Estimate Current Quarter
-0.19
EPS Estimate Next Quarter
-0.12

Analyst Recommendation

Buy
    84%Buy
    15%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Hookipa Pharma Inc.(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
2
2
2
Sell
00
00
1

Analyst Forecast

What analysts predicted

Upside of 514.46%

Current $0.76
Target $4.70

Company Financials

FY18Y/Y Change
Revenue
7.6M
-
Net Income
-16.2M
↑ 27.62%
Net Profit Margin
-212.83%
-
FY19Y/Y Change
Revenue
11.9M
↑ 56.53%
Net Income
-34.1M
↑ 110.3%
Net Profit Margin
-285.94%
↓ 73.11%
FY20Y/Y Change
Revenue
19.6M
↑ 63.99%
Net Income
-33.8M
↓ 1.01%
Net Profit Margin
-172.59%
↑ 113.35%
FY21Y/Y Change
Revenue
18.4M
↓ 5.8%
Net Income
-75.7M
↑ 123.86%
Net Profit Margin
-410.16%
↓ 237.57%
FY22Y/Y Change
Revenue
14.2M
↓ 22.76%
Net Income
-65.1M
↓ 13.9%
Net Profit Margin
-457.19%
↓ 47.03%
FY23Y/Y Change
Revenue
20.1M
↑ 41.27%
Net Income
-81.6M
↑ 25.23%
Net Profit Margin
-405.29%
↑ 51.9%
Q3 FY22Q/Q Change
Revenue
2.2M
↓ 18.79%
Net Income
-15.6M
↓ 4.82%
Net Profit Margin
-698.07%
↓ 102.44%
Q4 FY22Q/Q Change
Revenue
7.8M
↑ 251.03%
Net Income
-12.5M
↓ 19.44%
Net Profit Margin
-160.19%
↑ 537.88%
Q1 FY23Q/Q Change
Revenue
3.2M
↓ 59.43%
Net Income
-19.9M
↑ 58.57%
Net Profit Margin
-626.1%
↓ 465.91%
Q2 FY23Q/Q Change
Revenue
2.7M
↓ 15.65%
Net Income
-18.0M
↓ 9.4%
Net Profit Margin
-672.49%
↓ 46.39%
Q3 FY23Q/Q Change
Revenue
6.9M
↑ 156.33%
Net Income
-19.1M
↑ 5.83%
Net Profit Margin
-277.65%
↑ 394.84%
Q4 FY23Q/Q Change
Revenue
7.4M
↑ 7.86%
Net Income
-24.8M
↑ 30.17%
Net Profit Margin
-335.06%
↓ 57.41%
FY18Y/Y Change
Total Assets
68.3M
↓ 7.43%
Total Liabilities
23.9M
↓ 79.51%
FY19Y/Y Change
Total Assets
143.7M
↑ 110.61%
Total Liabilities
25.8M
↑ 8.36%
FY20Y/Y Change
Total Assets
187.8M
↑ 30.66%
Total Liabilities
31.7M
↑ 22.63%
FY21Y/Y Change
Total Assets
126.0M
↓ 32.89%
Total Liabilities
36.5M
↑ 15.02%
FY22Y/Y Change
Total Assets
170.5M
↑ 35.23%
Total Liabilities
67.9M
↑ 86.37%
FY23Y/Y Change
Total Assets
161.3M
↓ 5.35%
Total Liabilities
71.5M
↑ 5.22%
Q3 FY22Q/Q Change
Total Assets
151.5M
↓ 12.01%
Total Liabilities
38.2M
↓ 5.17%
Q4 FY22Q/Q Change
Total Assets
170.5M
↑ 12.49%
Total Liabilities
67.9M
↑ 77.95%
Q1 FY23Q/Q Change
Total Assets
163.1M
↓ 4.32%
Total Liabilities
79.6M
↑ 17.18%
Q2 FY23Q/Q Change
Total Assets
191.1M
↑ 17.18%
Total Liabilities
78.8M
↓ 1.04%
Q3 FY23Q/Q Change
Total Assets
164.0M
↓ 14.18%
Total Liabilities
69.0M
↓ 12.47%
Q4 FY23Q/Q Change
Total Assets
161.3M
↓ 1.63%
Total Liabilities
71.5M
↑ 3.66%
FY18Y/Y Change
Operating Cash Flow
-15.0M
↑ 25.9%
Investing Cash Flow
-2.2M
↑ 65.77%
Financing Cash Flow
6.9M
↓ 88.33%
FY19Y/Y Change
Operating Cash Flow
-41.7M
↑ 178.24%
Investing Cash Flow
-2.0M
↓ 7.02%
Financing Cash Flow
109.8M
↑ 1496.84%
FY20Y/Y Change
Operating Cash Flow
-39.3M
↓ 5.73%
Investing Cash Flow
-2.4M
↑ 18.61%
Financing Cash Flow
73.4M
↓ 33.1%
FY21Y/Y Change
Operating Cash Flow
-66.0M
↑ 67.81%
Investing Cash Flow
-12.6M
↑ 430.62%
Financing Cash Flow
-235.0K
↓ 100.32%
FY22Y/Y Change
Operating Cash Flow
-20.0M
↓ 69.71%
Investing Cash Flow
-5.0M
↓ 60.12%
Financing Cash Flow
72.3M
↓ 30853.62%
Q3 FY22Q/Q Change
Operating Cash Flow
-16.5M
↓ 10.08%
Investing Cash Flow
-958.0K
↓ 41.3%
Financing Cash Flow
127.0K
↓ 104.3%
Q4 FY22Q/Q Change
Operating Cash Flow
13.1M
↓ 179.58%
Investing Cash Flow
-599.0K
↓ 37.47%
Financing Cash Flow
-196.0K
↓ 254.33%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.8M
↓ 121.68%
Investing Cash Flow
-274.0K
↓ 54.26%
Financing Cash Flow
-735.0K
↑ 275.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-19.3M
↑ 578.83%
Investing Cash Flow
-445.0K
↑ 62.41%
Financing Cash Flow
45.8M
↓ 6333.33%

Technicals Summary

Sell

Neutral

Buy

Hookipa Pharma Inc. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Hookipa Pharma Inc.
Hookipa Pharma Inc.
4.03%
57.71%
4.0%
-93.63%
-94.54%
Moderna, Inc.
Moderna, Inc.
-2.96%
23.83%
-28.58%
-37.0%
331.65%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.23%
10.55%
10.52%
78.91%
167.64%
Novo Nordisk A/s
Novo Nordisk A/s
-6.56%
25.69%
48.76%
237.69%
410.4%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.23%
7.86%
19.8%
79.52%
133.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Hookipa Pharma Inc.
Hookipa Pharma Inc.
NA
NA
NA
-0.36
-0.85
-0.32
NA
0.91
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.8
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.3
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Hookipa Pharma Inc.
Hookipa Pharma Inc.
Buy
$75.7M
-94.54%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.1B
331.65%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
167.64%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
410.4%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.49%
28.42
36.68%

Institutional Holdings

  • Baker Bros Advisors LP

    8.21%
  • Artal Group S A

    5.73%
  • Knoll Capital Management LP

    5.58%
  • EcoR1 Capital, LLC

    4.64%
  • FMR Inc

    3.39%
  • Alyeska Investment Group, L.P.

    3.14%

Corporate Announcements

  • Hookipa Pharma Inc. Earnings

    Hookipa Pharma Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a

Organization
Hookipa Pharma Inc.
Employees
151
CEO
Mr. Joern Aldag
Industry
Pharmaceuticals: Major

FAQs